SLC5A2 and asthma: A recent retrospective comparative study also indicated that GLP-1R agonist treatment reduces the number of asthma exacerbations in patients with concurrent asthma and diabetes, as compared to other anti-diabetic drugs such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulfonylureas, or insulin [93].